Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Maravai LifeSciences Holdings, Inc. due to a class action complaint alleging breaches of fiduciary duties by the company's board of directors during a specified class period [2][8]. Group 1: Company Overview - Maravai LifeSciences Holdings, Inc. is facing legal scrutiny following a class action complaint filed on March 3, 2025, concerning events from August 7, 2024, to February 24, 2025 [2]. - The company announced a postponement of its fiscal 2024 earnings release and a delay in filing its annual report due to an error in revenue recognition, which resulted in approximately $3.9 million being incorrectly recorded [8]. Group 2: Financial Impact - Following the announcement of the revenue recognition error, Maravai's share price fell by $0.87, or 21.70%, closing at $3.14 per share on February 25, 2025, amid unusually heavy trading volume [8]. - The class action complaint alleges that the company made materially false and misleading statements regarding its financial health, including inadequate internal controls over financial reporting and overstated goodwill [8]. Group 3: Legal Actions - Investors who purchased Maravai stock during the specified class period are encouraged to contact Bragar Eagel & Squire for discussions regarding their legal rights and options [1][4]. - The law firm emphasizes that there is no cost or obligation for investors to inquire about these claims [4].

Core Viewpoint - Maravai LifeSciences Holdings, Inc. is under investigation for potential claims related to a class action complaint alleging breaches of fiduciary duties by its board of directors during a specified class period [1] Financial Reporting Issues - On February 25, 2025, Maravai announced a postponement of its fiscal 2024 earnings release and the filing of its annual report due to an error in revenue recognition, which resulted in approximately $3.9 million being incorrectly recorded [2] - The company identified a material weakness in its internal controls over revenue recognition and required additional time to assess a potential non-cash impairment charge related to goodwill from its acquisition of Alphazyme LLC [2] Class Action Allegations - The class action complaint alleges that Maravai's executives made materially false and misleading statements and failed to disclose adverse facts about the company's operations and financial reporting [3] - Specific allegations include inadequate internal controls over financial reporting, inaccurate revenue recognition, overstated goodwill, and misleading positive statements about the company's business prospects [3]

Core Viewpoint - A securities fraud lawsuit has been filed against Maravai LifeSciences Holdings, Inc. and certain executives due to issues related to revenue recognition and internal controls [1][3]. Group 1: Company Announcement - On February 25, 2025, Maravai announced a postponement of its fiscal 2024 earnings release and the filing of its annual report on Form 10-K due to an error in revenue recognition, which resulted in approximately $3.9 million being incorrectly recorded [2]. - The company identified a material weakness in its internal controls over revenue recognition and required additional time to assess a potential non-cash impairment charge related to goodwill from its acquisition of Alphazyme LLC [2]. Group 2: Stock Market Reaction - Following the announcement, Maravai's share price fell by $0.87, or 21.70%, closing at $3.14 per share on February 25, 2025, with unusually heavy trading volume [2]. Group 3: Lawsuit Allegations - The lawsuit alleges that Maravai failed to disclose inadequate internal controls over financial reporting related to revenue recognition, leading to inaccurate revenue recognition during fiscal 2024 and an overstated goodwill [3]. - It is claimed that the positive statements made by the defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis [3]. Group 4: Investor Eligibility - Investors who purchased Maravai common stock between August 7, 2024, and February 24, 2025, and experienced a decline in share value may be eligible to participate in the lawsuit [4]. Group 5: Next Steps for Investors - The deadline for seeking appointment as lead plaintiff is May 5, 2025, and a class has not yet been certified [5]. - Investors are encouraged to contact Block & Leviton for more information regarding their potential claims [5]. Group 6: Whistleblower Information - Individuals with non-public information about Maravai are encouraged to assist in the investigation or file a report with the SEC under the whistleblower program, which may offer rewards of up to 30% of any successful recovery [6]. Group 7: Firm Background - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].